ReWalk Robotics Ltd. (RWLK) - Form 20-F Summary
Business Context and Reporting Period
Company: ReWalk Robotics Ltd. (formerly Argo Medical Technologies Ltd.)
Reporting Period: Fiscal year ended December 31, 2014
Business Overview: ReWalk designs and commercializes exoskeletons (ReWalk Personal and ReWalk Rehabilitation) that enable individuals with spinal cord injuries to stand and walk. The company received FDA clearance for ReWalk Personal in June 2014, marking a significant milestone for U.S. commercialization. Manufacturing is outsourced to Sanmina Corporation in Israel.
Capital Structure: 11,978,554 ordinary shares outstanding as of December 31, 2014. The company completed its Initial Public Offering (IPO) in September 2014.
Key Financial Metrics (Year Ended Dec 31, 2014)
| Metric (in thousands, except per share) | 2014 | 2013 | 2012 |
|---|---|---|---|
| Revenues | $3,951 | $1,588 | $972 |
| Cost of Revenues | $4,106 | $2,017 | $983 |
| Gross Loss | $(621) | $(429) | $(11) |
| Operating Expenses | $19,304 | $8,316 | $5,748 |
| Operating Loss | $(19,925) | $(8,745) | $(5,759) |
| Net Loss | $(21,668) | $(12,177) | $(6,658) |
| Net Loss Per Share (Basic & Diluted) | $(6.34) | $(74.53) | $(41.26) |
| Cash and Cash Equivalents (Year End) | $41,829 | $8,860 | $769 |
| Total Assets | $47,665 | $11,059 | $2,094 |
| Accumulated Deficit | $(48,574) | $(26,906) | $(14,729) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 149% to $3.95 million, driven primarily by increased sales in the U.S. following FDA clearance in June 2014.
- Expense Surge: Operating expenses more than doubled to $19.3 million.
- R&D: Increased 248% to $8.6 million, largely due to a one-time non-cash share-based compensation award of $4.1 million to the founder and increased personnel costs.
- Sales & Marketing: Increased 81% to $7.4 million to support commercialization of ReWalk Personal.
- G&A: Increased 90% to $3.4 million due to public company compliance costs.
- Gross Loss: Gross loss widened to $0.6 million (16% of revenue) from $0.4 million (27% of revenue). The improvement in margin percentage was offset by a one-time $0.5 million expense related to the early settlement of a BIRD Foundation grant.
- Liquidity: Cash position improved significantly to $41.8 million, bolstered by $36.3 million in net proceeds from the September 2014 IPO and $12.8 million from a Series E preferred share investment.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring net losses for at least the next two years as it expands sales, marketing, and R&D. The company believes current cash resources are sufficient to meet requirements for at least 24 months. Future growth depends on third-party reimbursement approvals and market acceptance.
Key Risks:
- Reimbursement: No uniform policy exists for exoskeleton coverage. Private insurers currently do not cover personal use; reliance is on self-payers and case-by-case approvals. CMS (Medicare/Medicaid) decisions could take 3-5 years.
- Market Acceptance: The market for medical exoskeletons is new and unproven. Adoption depends on clinical data proving secondary health benefits and overcoming user limitations (e.g., weight, need for a companion).
- Manufacturing Concentration: Reliance on a single contract manufacturer (Sanmina) in Israel creates supply chain and geopolitical risks.
- Regulatory: Subject to FDA and international regulations; failure to comply could result in recalls or market withdrawal.
- Intellectual Property: Risks of infringement claims or inability to protect patents in key markets.
Investor Verification Checklist
- Reimbursement Progress: Verify the status of case-by-case insurance approvals and any new commitments from government payors (e.g., VA, CMS).
- Unit Economics: Assess the trajectory of gross margins as manufacturing scales and the impact of the one-time BIRD grant settlement on future profitability.
- Cash Burn Rate: Monitor operating cash flow usage against the $41.8 million cash balance to validate the 24-month runway estimate.
- Share-Based Compensation: Review future equity grant plans to understand the potential for recurring non-cash expense dilution similar to the $4.1 million founder award in 2014.
- Geopolitical Exposure: Evaluate the impact of potential disruptions at the Israeli manufacturing facility on supply chain continuity.